Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
ZN-c3 in Adult Participants with Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-11-26
- Target Recruit Count
- 82
- Registration Number
- NCT05743036
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Alliance for Multispecialty Research, LLC, Merriam, Kansas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Phase I Trial of Adagrasib (MRTX849) in Combination with Cetuximab and Irinotecan in Patients with Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05722327
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 100
- Registration Number
- NCT05720559
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 394
- Registration Number
- NCT05710406
- Locations
- 🇺🇸
The Queen's Medical Center - West Oahu, 'Ewa Beach, Hawaii, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
🇺🇸Rush-Copley Healthcare Center, Yorkville, Illinois, United States
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 90
- Registration Number
- NCT05694936
- Locations
- 🇦🇺
Eben-Marie Garzina, Ballarat Central, Victoria, Australia
🇦🇺Southern Adelaide Local Health Network Incorporated, Bedford Park, South Australia, Australia
🇦🇺Austin Health, Melbourne, Victoria, Australia
A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Shanghai Celfuture Biotech Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT05684211
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- C4 Therapeutics, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT05668585
- Locations
- 🇪🇸
NEXT Oncology Barcelona, Barcelona, Spain
🇺🇸University of Wisconsin, Madison, Wisconsin, United States
🇫🇷Institut Bergonie, Bordeaux Cedex, France
The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer
- First Posted Date
- 2022-11-28
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 93
- Registration Number
- NCT05628038
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- SOTIO Biotech AG
- Target Recruit Count
- 16
- Registration Number
- NCT05619172
- Locations
- 🇧🇪
Grand Hopital de Charleroi - Hopital Notre Dame, Charleroi, Belgium
🇧🇪Universitair Ziekenhuis Gent, Gent, Belgium
🇪🇸Hospital Clinic de Barcelona, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.